Verastem, Inc.
Verastem, Inc. (2VSA.F) Stock Competitors & Peer Comparison
See (2VSA.F) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2VSA.F | €4.16 | -8.77% | 305M | -1.69 | -€2.61 | N/A |
| NOV.DE | €30.67 | -3.08% | 135.2B | 9.88 | €3.08 | +5.14% |
| VX1.DE | €382.85 | -3.22% | 97.3B | 29.03 | €13.19 | N/A |
| DUL.DE | €276.00 | -3.21% | 36.8B | 137.94 | €2.01 | N/A |
| 22UA.F | €74.55 | -2.61% | 18.5B | -15.68 | -€4.70 | N/A |
| 0QF.F | €42.90 | -8.16% | 18.4B | -7.58 | -€6.14 | N/A |
| BM8.DE | €61.96 | -1.71% | 11.8B | 88.51 | €0.70 | N/A |
| EX9.DE | €32.28 | +1.22% | 9.2B | 35.47 | €0.91 | N/A |
| BBZA.DE | €46.35 | -1.90% | 2.5B | -5.37 | -€8.60 | +5.32% |
| MOR.DE | €67.25 | -0.66% | 2.5B | -12.16 | -€5.53 | N/A |
Stock Comparison
2VSA.F vs NOV.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, NOV.DE has a market cap of 135.2B. Regarding current trading prices, 2VSA.F is priced at €4.16, while NOV.DE trades at €30.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas NOV.DE's P/E ratio is 9.88. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to NOV.DE's ROE of +0.61%. Regarding short-term risk, 2VSA.F is less volatile compared to NOV.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check NOV.DE's competition here
2VSA.F vs VX1.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, VX1.DE has a market cap of 97.3B. Regarding current trading prices, 2VSA.F is priced at €4.16, while VX1.DE trades at €382.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas VX1.DE's P/E ratio is 29.03. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to VX1.DE's ROE of +0.23%. Regarding short-term risk, 2VSA.F is less volatile compared to VX1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check VX1.DE's competition here
2VSA.F vs DUL.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, DUL.DE has a market cap of 36.8B. Regarding current trading prices, 2VSA.F is priced at €4.16, while DUL.DE trades at €276.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas DUL.DE's P/E ratio is 137.94. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to DUL.DE's ROE of +0.89%. Regarding short-term risk, 2VSA.F is more volatile compared to DUL.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check DUL.DE's competition here
2VSA.F vs 22UA.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 22UA.F has a market cap of 18.5B. Regarding current trading prices, 2VSA.F is priced at €4.16, while 22UA.F trades at €74.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 22UA.F's P/E ratio is -15.68. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 22UA.F's ROE of -0.06%. Regarding short-term risk, 2VSA.F is less volatile compared to 22UA.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 22UA.F's competition here
2VSA.F vs 0QF.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 0QF.F has a market cap of 18.4B. Regarding current trading prices, 2VSA.F is priced at €4.16, while 0QF.F trades at €42.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 0QF.F's P/E ratio is -7.58. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 0QF.F's ROE of -0.30%. Regarding short-term risk, 2VSA.F is less volatile compared to 0QF.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 0QF.F's competition here
2VSA.F vs BM8.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, BM8.DE has a market cap of 11.8B. Regarding current trading prices, 2VSA.F is priced at €4.16, while BM8.DE trades at €61.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas BM8.DE's P/E ratio is 88.51. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to BM8.DE's ROE of +0.11%. Regarding short-term risk, 2VSA.F is less volatile compared to BM8.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check BM8.DE's competition here
2VSA.F vs EX9.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, EX9.DE has a market cap of 9.2B. Regarding current trading prices, 2VSA.F is priced at €4.16, while EX9.DE trades at €32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas EX9.DE's P/E ratio is 35.47. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to EX9.DE's ROE of +0.27%. Regarding short-term risk, 2VSA.F is less volatile compared to EX9.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check EX9.DE's competition here
2VSA.F vs BBZA.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, BBZA.DE has a market cap of 2.5B. Regarding current trading prices, 2VSA.F is priced at €4.16, while BBZA.DE trades at €46.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas BBZA.DE's P/E ratio is -5.37. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to BBZA.DE's ROE of -0.20%. Regarding short-term risk, 2VSA.F is less volatile compared to BBZA.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check BBZA.DE's competition here
2VSA.F vs MOR.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, MOR.DE has a market cap of 2.5B. Regarding current trading prices, 2VSA.F is priced at €4.16, while MOR.DE trades at €67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas MOR.DE's P/E ratio is -12.16. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to MOR.DE's ROE of -1.84%. Regarding short-term risk, 2VSA.F is less volatile compared to MOR.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check MOR.DE's competition here
2VSA.F vs BIO3.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, BIO3.DE has a market cap of 1.6B. Regarding current trading prices, 2VSA.F is priced at €4.16, while BIO3.DE trades at €32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas BIO3.DE's P/E ratio is -50.79. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to BIO3.DE's ROE of -0.07%. Regarding short-term risk, 2VSA.F is more volatile compared to BIO3.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check BIO3.DE's competition here
2VSA.F vs BIO.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, BIO.DE has a market cap of 1.3B. Regarding current trading prices, 2VSA.F is priced at €4.16, while BIO.DE trades at €39.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas BIO.DE's P/E ratio is -62.22. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to BIO.DE's ROE of -0.07%. Regarding short-term risk, 2VSA.F is less volatile compared to BIO.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check BIO.DE's competition here
2VSA.F vs NVV1.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, NVV1.F has a market cap of 1.2B. Regarding current trading prices, 2VSA.F is priced at €4.16, while NVV1.F trades at €7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas NVV1.F's P/E ratio is 3.33. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to NVV1.F's ROE of -5.46%. Regarding short-term risk, 2VSA.F is less volatile compared to NVV1.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check NVV1.F's competition here
2VSA.F vs IMU.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, IMU.DE has a market cap of 1.1B. Regarding current trading prices, 2VSA.F is priced at €4.16, while IMU.DE trades at €5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas IMU.DE's P/E ratio is -9.22. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to IMU.DE's ROE of -0.93%. Regarding short-term risk, 2VSA.F is less volatile compared to IMU.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check IMU.DE's competition here
2VSA.F vs GBY.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, GBY.DE has a market cap of 884.7M. Regarding current trading prices, 2VSA.F is priced at €4.16, while GBY.DE trades at €5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas GBY.DE's P/E ratio is -4.38. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to GBY.DE's ROE of -0.41%. Regarding short-term risk, 2VSA.F is less volatile compared to GBY.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check GBY.DE's competition here
2VSA.F vs 5CV.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 5CV.F has a market cap of 879.5M. Regarding current trading prices, 2VSA.F is priced at €4.16, while 5CV.F trades at €3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 5CV.F's P/E ratio is 6.85. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 5CV.F's ROE of +0.18%. Regarding short-term risk, 2VSA.F is less volatile compared to 5CV.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 5CV.F's competition here
2VSA.F vs 5CV.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 5CV.DE has a market cap of 879.5M. Regarding current trading prices, 2VSA.F is priced at €4.16, while 5CV.DE trades at €3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 5CV.DE's P/E ratio is 6.85. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 5CV.DE's ROE of +0.18%. Regarding short-term risk, 2VSA.F is less volatile compared to 5CV.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 5CV.DE's competition here
2VSA.F vs 2EM.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 2EM.DE has a market cap of 586M. Regarding current trading prices, 2VSA.F is priced at €4.16, while 2EM.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 2EM.DE's P/E ratio is 34.38. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 2EM.DE's ROE of +0.20%. Regarding short-term risk, 2VSA.F is less volatile compared to 2EM.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 2EM.DE's competition here
2VSA.F vs 94E.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 94E.F has a market cap of 338.1M. Regarding current trading prices, 2VSA.F is priced at €4.16, while 94E.F trades at €5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 94E.F's P/E ratio is -5.71. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 94E.F's ROE of -0.84%. Regarding short-term risk, 2VSA.F is more volatile compared to 94E.F. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check 94E.F's competition here
2VSA.F vs FYB.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, FYB.DE has a market cap of 312.1M. Regarding current trading prices, 2VSA.F is priced at €4.16, while FYB.DE trades at €17.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas FYB.DE's P/E ratio is -1.83. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to FYB.DE's ROE of -0.39%. Regarding short-term risk, 2VSA.F is less volatile compared to FYB.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check FYB.DE's competition here
2VSA.F vs VSC.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, VSC.DE has a market cap of 150.7M. Regarding current trading prices, 2VSA.F is priced at €4.16, while VSC.DE trades at €2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas VSC.DE's P/E ratio is -7.27. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to VSC.DE's ROE of -0.90%. Regarding short-term risk, 2VSA.F is more volatile compared to VSC.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check VSC.DE's competition here
2VSA.F vs HPHA.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, HPHA.DE has a market cap of 141.3M. Regarding current trading prices, 2VSA.F is priced at €4.16, while HPHA.DE trades at €2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas HPHA.DE's P/E ratio is -5.39. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to HPHA.DE's ROE of -1.23%. Regarding short-term risk, 2VSA.F is more volatile compared to HPHA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check HPHA.DE's competition here
2VSA.F vs IF0.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, IF0.DE has a market cap of 129.9M. Regarding current trading prices, 2VSA.F is priced at €4.16, while IF0.DE trades at €2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas IF0.DE's P/E ratio is -2.43. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to IF0.DE's ROE of -0.45%. Regarding short-term risk, 2VSA.F is more volatile compared to IF0.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check IF0.DE's competition here
2VSA.F vs 88Q.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 88Q.DE has a market cap of 92.1M. Regarding current trading prices, 2VSA.F is priced at €4.16, while 88Q.DE trades at €5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 88Q.DE's P/E ratio is -5.22. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 88Q.DE's ROE of -0.75%. Regarding short-term risk, 2VSA.F is less volatile compared to 88Q.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 88Q.DE's competition here
2VSA.F vs GBM.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, GBM.F has a market cap of 91.2M. Regarding current trading prices, 2VSA.F is priced at €4.16, while GBM.F trades at €1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas GBM.F's P/E ratio is -0.84. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to GBM.F's ROE of -0.80%. Regarding short-term risk, 2VSA.F is more volatile compared to GBM.F. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check GBM.F's competition here
2VSA.F vs BNN.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, BNN.DE has a market cap of 52M. Regarding current trading prices, 2VSA.F is priced at €4.16, while BNN.DE trades at €2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas BNN.DE's P/E ratio is -4.86. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to BNN.DE's ROE of -3.38%. Regarding short-term risk, 2VSA.F is more volatile compared to BNN.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check BNN.DE's competition here
2VSA.F vs C6O.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, C6O.DE has a market cap of 13.2M. Regarding current trading prices, 2VSA.F is priced at €4.16, while C6O.DE trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas C6O.DE's P/E ratio is -0.05. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to C6O.DE's ROE of +1.21%. Regarding short-term risk, 2VSA.F is less volatile compared to C6O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check C6O.DE's competition here
2VSA.F vs GBMB.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, GBMB.F has a market cap of 12.6M. Regarding current trading prices, 2VSA.F is priced at €4.16, while GBMB.F trades at €0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas GBMB.F's P/E ratio is -0.08. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to GBMB.F's ROE of -0.80%. Regarding short-term risk, 2VSA.F is less volatile compared to GBMB.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check GBMB.F's competition here
2VSA.F vs CNW.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, CNW.DE has a market cap of 6.5M. Regarding current trading prices, 2VSA.F is priced at €4.16, while CNW.DE trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas CNW.DE's P/E ratio is -0.44. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to CNW.DE's ROE of -0.49%. Regarding short-term risk, 2VSA.F is less volatile compared to CNW.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check CNW.DE's competition here
2VSA.F vs LD6.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, LD6.F has a market cap of 4.5M. Regarding current trading prices, 2VSA.F is priced at €4.16, while LD6.F trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas LD6.F's P/E ratio is -1.01. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to LD6.F's ROE of -3.29%. Regarding short-term risk, 2VSA.F is less volatile compared to LD6.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check LD6.F's competition here
2VSA.F vs MDG1.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, MDG1.DE has a market cap of 2M. Regarding current trading prices, 2VSA.F is priced at €4.16, while MDG1.DE trades at €0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas MDG1.DE's P/E ratio is -0.11. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to MDG1.DE's ROE of -0.56%. Regarding short-term risk, 2VSA.F is less volatile compared to MDG1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check MDG1.DE's competition here
2VSA.F vs MDG1.F Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, MDG1.F has a market cap of 436.2K. Regarding current trading prices, 2VSA.F is priced at €4.16, while MDG1.F trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas MDG1.F's P/E ratio is -0.02. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to MDG1.F's ROE of -0.56%. Regarding short-term risk, 2VSA.F is more volatile compared to MDG1.F. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check MDG1.F's competition here
2VSA.F vs T5O.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, T5O.DE has a market cap of 164.4K. Regarding current trading prices, 2VSA.F is priced at €4.16, while T5O.DE trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas T5O.DE's P/E ratio is -0.25. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to T5O.DE's ROE of -1.91%. Regarding short-term risk, 2VSA.F is less volatile compared to T5O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check T5O.DE's competition here
2VSA.F vs AXP.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, AXP.DE has a market cap of 0. Regarding current trading prices, 2VSA.F is priced at €4.16, while AXP.DE trades at €153.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas AXP.DE's P/E ratio is 59.63. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to AXP.DE's ROE of +0.05%. Regarding short-term risk, 2VSA.F is more volatile compared to AXP.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check AXP.DE's competition here
2VSA.F vs 8CC1.DU Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, 8CC1.DU has a market cap of 0. Regarding current trading prices, 2VSA.F is priced at €4.16, while 8CC1.DU trades at €0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas 8CC1.DU's P/E ratio is N/A. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to 8CC1.DU's ROE of N/A. Regarding short-term risk, 2VSA.F is less volatile compared to 8CC1.DU. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 8CC1.DU's competition here
2VSA.F vs CNWK.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, CNWK.DE has a market cap of 0. Regarding current trading prices, 2VSA.F is priced at €4.16, while CNWK.DE trades at €2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas CNWK.DE's P/E ratio is -5.82. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to CNWK.DE's ROE of -0.86%. Regarding short-term risk, 2VSA.F is less volatile compared to CNWK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check CNWK.DE's competition here
2VSA.F vs MGNK.DE Comparison April 2026
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 305M. In comparison, MGNK.DE has a market cap of 0. Regarding current trading prices, 2VSA.F is priced at €4.16, while MGNK.DE trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.69, whereas MGNK.DE's P/E ratio is N/A. In terms of profitability, 2VSA.F's ROE is -18.50%, compared to MGNK.DE's ROE of +4.09%. Regarding short-term risk, 2VSA.F is less volatile compared to MGNK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check MGNK.DE's competition here